Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Harley-Davidson Inc (HOG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Harley-Davidson IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Harley-Davidson Inc vs IDEXX Laboratories, Inc. — how do they compare? Harley-Davidson Inc trades at $26.06 (market cap $2.78B), while IDEXX Laboratories, Inc. trades at $571.01 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 16.6× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.75% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

HOGIDXX
Market Cap
$2.78B$46.22B
Sector
Consumer CyclicalHealth
52-Week High
$31.03$766.68
52-Week Low
$17.19$526.44
Enterprise Value
$3.19B$47.12B
Dividend Yield
2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Harley-Davidson Inc

Harley-Davidson (HOG) trades at $25.95, down 0.57% with a bullish technical signal. The company reported Q2 2026 EPS of $0.75 beating estimates of $0.645, though revenue declined to $4.47B in 2025 from $5.8B in 2022. Valuation metrics appear reasonable with P/E of 14.84 and P/S of 0.72. Recent news highlights production returning to US facilities and raised 2026 guidance following stronger North American sales.

The outlook remains cautiously optimistic with analyst consensus at $26.00 target. Key opportunities include cost-cutting initiatives and domestic production advantages, while risks involve ongoing revenue pressure, competitive threats from Indian Motorcycle, and margin compression from rising raw material costs evident in recent quarterly results.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.

The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Harley-Davidson Inc

Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.

Read more on HOG

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX